JP2022505158A5 - - Google Patents

Info

Publication number
JP2022505158A5
JP2022505158A5 JP2021521098A JP2021521098A JP2022505158A5 JP 2022505158 A5 JP2022505158 A5 JP 2022505158A5 JP 2021521098 A JP2021521098 A JP 2021521098A JP 2021521098 A JP2021521098 A JP 2021521098A JP 2022505158 A5 JP2022505158 A5 JP 2022505158A5
Authority
JP
Japan
Application number
JP2021521098A
Other languages
Japanese (ja)
Other versions
JP2022505158A (ja
JPWO2020081841A5 (https=
JP7453971B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056777 external-priority patent/WO2020081841A1/en
Publication of JP2022505158A publication Critical patent/JP2022505158A/ja
Publication of JPWO2020081841A5 publication Critical patent/JPWO2020081841A5/ja
Publication of JP2022505158A5 publication Critical patent/JP2022505158A5/ja
Application granted granted Critical
Publication of JP7453971B2 publication Critical patent/JP7453971B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521098A 2018-10-19 2019-10-17 Nkエンゲージャー分子およびその使用方法 Active JP7453971B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862747983P 2018-10-19 2018-10-19
US62/747,983 2018-10-19
PCT/US2019/056777 WO2020081841A1 (en) 2018-10-19 2019-10-17 Nk engager molecules and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2022505158A JP2022505158A (ja) 2022-01-14
JPWO2020081841A5 JPWO2020081841A5 (https=) 2022-10-19
JP2022505158A5 true JP2022505158A5 (https=) 2022-10-19
JP7453971B2 JP7453971B2 (ja) 2024-03-21

Family

ID=70284811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521098A Active JP7453971B2 (ja) 2018-10-19 2019-10-17 Nkエンゲージャー分子およびその使用方法

Country Status (9)

Country Link
US (2) US12319737B2 (https=)
EP (1) EP3867278A4 (https=)
JP (1) JP7453971B2 (https=)
KR (1) KR102897353B1 (https=)
CN (2) CN112912400B (https=)
AU (1) AU2019361096A1 (https=)
CA (1) CA3114707A1 (https=)
IL (1) IL282193B2 (https=)
WO (1) WO2020081841A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2023043958A1 (en) * 2021-09-16 2023-03-23 Gt Biopharma, Inc. Pd-l1 targeting fusion proteins and methods of use thereof
CN117482246B (zh) * 2022-12-30 2024-10-15 英百瑞(杭州)生物医药有限公司 抗cd33/cll1双特异性抗体-自然杀伤细胞偶联物及其用途
JPWO2024248037A1 (https=) * 2023-05-30 2024-12-05
WO2025136820A1 (en) * 2023-12-18 2025-06-26 Regents Of The University Of Minnesota Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use
WO2025223505A1 (zh) * 2024-04-24 2025-10-30 南京吉盛澳玛生物医药有限公司 先天免疫超级连接器与完全免疫抗体的设计、制备及应用
CN118325927A (zh) * 2024-06-13 2024-07-12 广州安捷生物医学技术有限公司 编码nk细胞衔接器和car的多核苷酸及包含其的修饰细胞

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511013A1 (en) 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP2006513225A (ja) 2002-12-20 2006-04-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 化学療法剤と組み合わせたリンホトキシンβ受容体因子
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
CA2533753C (en) 2004-03-19 2012-10-16 Morinaga Milk Industry Co., Ltd. Drug for cancer therapy
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
EP2111550B1 (en) 2007-01-26 2011-11-30 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2197909A4 (en) 2007-08-24 2014-12-03 Univ Minnesota REAGENTS ON RECIPES
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012017522A1 (ja) 2010-08-03 2012-02-09 富士通株式会社 検証プログラムおよび検証装置
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
CN102251013A (zh) 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
WO2013039883A1 (en) 2011-09-12 2013-03-21 Abbvie Biotherapeutics Inc. Artificial nk cells and uses thereof
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
EP3470431A1 (en) 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
EP3447072A3 (en) 2013-03-05 2019-05-22 Baylor College of Medicine Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
KR20170037625A (ko) 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
US20180021378A1 (en) 2014-12-31 2018-01-25 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
EP3310378B1 (en) 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1 antibodies and methods of use
MX389194B (es) 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
CA3055200A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
SG11202002298PA (en) 2017-09-14 2020-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
WO2019246593A2 (en) * 2018-06-22 2019-12-26 Fred Hutchinson Cancer Research Center Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders

Similar Documents

Publication Publication Date Title
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
JP2022505158A5 (https=)
BR112021017728A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112021017732A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021018484A2 (https=)
BR112021017949A2 (https=)
BR112021018084A2 (https=)
BR112021017983A2 (https=)
BR112021018193A2 (https=)
BR112021017847A2 (https=)
BR112021013854A2 (https=)
CN304980406S (https=)
CN304975308S (https=)